• Strategic Technologies

Press Release: Over £100m cash boost to manufacture millions of doses of COVID-19 vaccine

- New state-of-the-art centre to scale up COVID-19 vaccine and gene therapy manufacturing gets £100m investment - Additional £4.7m for new training facilities and an online learning platform to boost vaccine as well as cell and gene therapy skills - New centre and skills vital for the UK’s ability respond to diseases like coronavirus, and potential future pandemics

CGT Catapult Annual Review 2020 highlights impact on growth and productivity in the UK cell and gene therapy industry

The 2020 annual report released today presents Cell and Gene Therapy Catapult's achievements, collaborations and initiatives from the past year and their impact in enhancing growth, productivity and supporting the development and commercialisation of cell and gene therapies.

Medicines Discovery Catapult, Retrogenix and Peak Proteins collaborate to identify target receptors for COVID-19

Supporting the race for treatments new collaboration launched to drive understanding of COVID-19 Medicines Discovery Catapult, Retrogenix and Peak Proteins collaborate to identify target receptors for COVID-19

Evonetix collaborates with imec to scale-up chip-based technology production for third generation DNA synthesis platform

Evonetix, the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, today announced it has partnered with imec to increase production of Evonetix’s proprietary microelectromechanical systems (MEMS)-based silicon chips, enabling the platform to be manufactured at a commercial scale.

CGT Catapult hosts second annual workshop to address digital challenges in adoption of advanced therapies by the NHS

Experts addressed different possible models for optimising data collection to support the adoption of cell and gene therapies in the UK. Barriers to digital integration, post-launch data collection and outcomes-based reimbursement were the primary focus of the day.

AMR Centre candidate targets superbugs with problem metallo-β-lactamase enzymes

The AMR Centre has nominated a preclinical candidate in its program that tackles drug resistance conferred by NDM-1 and other metallo-β-lactamases (MBL).

Evonetix expands facilities and relocates to central Cambridge, UK

Evonetix, the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, today announced it has moved to Coldham’s Business Park, Cambridge, UK. The new facility will enable the continued growth of the Company as it continues in its mission to develop a desktop DNA synthesis platform based on its proprietary silicon chip.

Enesi Pharma Secures Innovate UK Funding to Enable Scalable Aseptic Manufacturing of ImplaVax®-enabled Solid Dose Viral Vector Vaccines

Enesi Pharma, the innovative pharmaceutical company developing unique injectable solid dose drug-device vaccine products, is delighted to announce that it has secured substantial funding from Innovate UK, the UK’s innovation agency, under the Biomedical Catalyst 2019 Round 1: Early and Late Stage Awards Initiative.

Cobra Biologics and Symbiosis Complete £4.8m Viral Vector Supply Chain Collaboration

Developing world-leading capabilities in drug substance and drug product viral vector production for gene and immunotherapy.

Guest blog | Sean Morgan-Jones | UK Biotech PLC is Totally Smashing It...

‘The UK is leading a two speed Europe’ (McKinsey & Company, Biotech in Europe: Scaling Innovation May 20, 2019). One of the key findings and contrary to the received wisdom, is that the UK is totally smashing it on all measures as a Biotech hot spot according to research presented at BioEquity Europe in Barcelona by McKinsey & Company looking at where's hot and where's not. Of the 1,000 European Biotechs established since 2012 the UK is leading by a country mile and represents 35% of all new Biotechs and according to the report and is leading a two speed Europe (with Germany, France and Spain in relative decline).